While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js ...
New research at the University of Alberta may make it easier to diagnose serious diseases that disrupt the body's energy ...
Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...
Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...
FSHD is the second most common form of muscular dystrophy after the Duchenne type ... with a nanobody developed by Sanofi that targets muscle cells. Nanobodies are smaller than conventional ...
IPS HEART has now shown GIVI-MPCs create new human muscle with full length human dystrophin in dystrophic pigs, young and extremely aged Duchenne Muscular Dystrophy (DMD) mice and in a sarcopenia ...
Top-line Phase 3 trial data show ambulatory boys with Duchenne continued with motor improvements two years after a single ...
Entrada Therapeutics plans to initiate ELEVATE-44-201 trial for ENTR-601-44 in Duchenne muscular dystrophy by ... integrity and function of muscle cells. Lack of functional dystrophin leads ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback